Literature DB >> 19164761

Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia.

Federica Agosta1, Keith A Vossel, Bruce L Miller, Raffaella Migliaccio, Stephen J Bonasera, Massimo Filippi, Adam L Boxer, Anna Karydas, Katherine L Possin, Maria Luisa Gorno-Tempini.   

Abstract

Apolipoprotein epsilon4 (apoE4) has been strongly linked with Alzheimer's disease (AD) and contributes to several other neurological disorders. We investigated the influence of epsilon4 allele carrier status on the pattern of gray matter atrophy and disease severity in 51 patients with probable AD and 31 patients with behavioral variant frontotemporal dementia (bvFTD), compared with 56 healthy controls. Voxel-based morphometry was performed by using statistical parametric mapping. The epsilon4 allele frequency was higher in the AD group (P < 0.001) than the controls but not in the bvFTD group. No differences in demographic or cognitive profiles were observed between epsilon4 allele carriers and noncarriers within any of the diagnostic groups. However, epsilon4 carrier status was associated with more severe brain atrophy in disease-specific regions compared with noncarriers in both AD and bvFTD. AD epsilon4 carriers showed greater atrophy in the bilateral parietal cortex and right hippocampus, and bvFTD epsilon4 carriers demonstrated greater atrophy in the bilateral medial, dorsolateral, and orbital frontal cortex, anterior insula, and cingulate cortex with right predominance. This regional epsilon4 effect is consistent with the hypothesis that apoE may affect the morphologic expression uniquely in different neurodegenerative diseases. The atrophy patterns in epsilon4 carriers may indicate that they are at greater risk for clinical progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19164761      PMCID: PMC2644156          DOI: 10.1073/pnas.0812697106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Association between apolipoprotein E e4 allele and arteriosclerosis, cerebral amyloid angiopathy, and cerebral white matter damage in Alzheimer's disease.

Authors:  J Tian; J Shi; K Bailey; C L Lendon; S M Pickering-Brown; D M A Mann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

2.  Patterns of brain atrophy in frontotemporal dementia and semantic dementia.

Authors:  H J Rosen; M L Gorno-Tempini; W P Goldman; R J Perry; N Schuff; M Weiner; R Feiwell; J H Kramer; B L Miller
Journal:  Neurology       Date:  2002-01-22       Impact factor: 9.910

3.  Familial dementia with lewy bodies: a clinical and neuropathological study of 2 families.

Authors:  Debby W Tsuang; Aaron M Dalan; Charisma J Eugenio; Parvonah Poorkaj; Pornprot Limprasert; Albert R La Spada; Ellen J Steinbart; Thomas D Bird; James B Leverenz
Journal:  Arch Neurol       Date:  2002-10

4.  Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease.

Authors:  D M Holtzman; K R Bales; T Tenkova; A M Fagan; M Parsadanian; L J Sartorius; B Mackey; J Olney; D McKeel; D Wozniak; S M Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

5.  Apolipoprotein E genotype and hippocampal asymmetry in Alzheimer's disease: a volumetric MRI study.

Authors:  C Geroldi; M P Laakso; C DeCarli; A Beltramello; A Bianchetti; H Soininen; M Trabucchi; G B Frisoni
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-01       Impact factor: 10.154

6.  Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease.

Authors:  G M McKhann; M S Albert; M Grossman; B Miller; D Dickson; J Q Trojanowski
Journal:  Arch Neurol       Date:  2001-11

7.  Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E epsilon4 allele.

Authors:  Etsuro Mori; KangUk Lee; Minoru Yasuda; Mamoru Hashimoto; Hiroaki Kazui; Nobutsugu Hirono; Mieko Matsui
Journal:  Ann Neurol       Date:  2002-02       Impact factor: 10.422

8.  Apolipoprotein E polymorphism in German patients with frontotemporal degeneration.

Authors:  M Riemenschneider; J Diehl; U Müller; H Förstl; A Kurz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-05       Impact factor: 10.154

9.  APOE and modulation of Alzheimer's and frontotemporal dementia.

Authors:  M Boccardi; F Sabattoli; C Testa; A Beltramello; H Soininen; G B Frisoni
Journal:  Neurosci Lett       Date:  2004-02-19       Impact factor: 3.046

10.  Automatic differentiation of anatomical patterns in the human brain: validation with studies of degenerative dementias.

Authors:  Catriona D Good; Rachael I Scahill; Nick C Fox; John Ashburner; Karl J Friston; Dennis Chan; William R Crum; Martin N Rossor; Richard S J Frackowiak
Journal:  Neuroimage       Date:  2002-09       Impact factor: 6.556

View more
  79 in total

1.  Intracranial volume and dementia: some evidence in support of the cerebral reserve hypothesis.

Authors:  D F Tate; E S Neeley; M C Norton; J T Tschanz; M J Miller; L Wolfson; C Hulette; C Leslie; K A Welsh-Bohmer; B Plassman; Erin D Bigler
Journal:  Brain Res       Date:  2010-12-21       Impact factor: 3.252

2.  APOE genotype modulates proton magnetic resonance spectroscopy metabolites in the aging brain.

Authors:  Jesus J Gomar; Marc L Gordon; Dwight Dickinson; Peter B Kingsley; Aziz M Uluğ; Lynda Keehlisen; Sarah Huet; Justin J Buthorn; Jeremy Koppel; Erica Christen; Concepcion Conejero-Goldberg; Peter Davies; Terry E Goldberg
Journal:  Biol Psychiatry       Date:  2013-07-05       Impact factor: 13.382

3.  Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease.

Authors:  David A Wolk; Bradford C Dickerson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

4.  Association of gray matter atrophy with age, β-amyloid, and cognition in aging.

Authors:  Hwamee Oh; Cindee Madison; Sylvia Villeneuve; Candace Markley; William J Jagust
Journal:  Cereb Cortex       Date:  2013-02-06       Impact factor: 5.357

5.  Incidence and impact of subclinical epileptiform activity in Alzheimer's disease.

Authors:  Keith A Vossel; Kamalini G Ranasinghe; Alexander J Beagle; Danielle Mizuiri; Susanne M Honma; Anne F Dowling; Sonja M Darwish; Victoria Van Berlo; Deborah E Barnes; Mary Mantle; Anna M Karydas; Giovanni Coppola; Erik D Roberson; Bruce L Miller; Paul A Garcia; Heidi E Kirsch; Lennart Mucke; Srikantan S Nagarajan
Journal:  Ann Neurol       Date:  2016-11-07       Impact factor: 10.422

6.  Frontolimbic atrophy is associated with agitation and aggression in mild cognitive impairment and Alzheimer's disease.

Authors:  Paula T Trzepacz; Peng Yu; Phani K Bhamidipati; Brian Willis; Tammy Forrester; Linda Tabas; Adam J Schwarz; Andrew J Saykin
Journal:  Alzheimers Dement       Date:  2012-12-17       Impact factor: 21.566

7.  Surface fluid registration of conformal representation: application to detect disease burden and genetic influence on hippocampus.

Authors:  Jie Shi; Paul M Thompson; Boris Gutman; Yalin Wang
Journal:  Neuroimage       Date:  2013-04-13       Impact factor: 6.556

8.  Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden.

Authors:  Gil D Rabinovici; Ansgar J Furst; Adi Alkalay; Caroline A Racine; James P O'Neil; Mustafa Janabi; Suzanne L Baker; Neha Agarwal; Stephen J Bonasera; Elizabeth C Mormino; Michael W Weiner; Maria L Gorno-Tempini; Howard J Rosen; Bruce L Miller; William J Jagust
Journal:  Brain       Date:  2010-01-15       Impact factor: 13.501

Review 9.  Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight.

Authors:  Yang Shi; David M Holtzman
Journal:  Nat Rev Immunol       Date:  2018-12       Impact factor: 53.106

Review 10.  Molecular basis of etiological implications in Alzheimer's disease: focus on neuroinflammation.

Authors:  Rituraj Niranjan
Journal:  Mol Neurobiol       Date:  2013-02-19       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.